Alligator Bioscience has reported updated results with its CD40 agonist mitazalimab as a first-line treatment for advanced pancreatic cancer, a disease with few treatment options.<
FibroGen has pulled the plug on its lead drug pamrevlumab after two failed trials in pancreatic cancer and immediately announced plans to shed three-quarters of its workforce.
